Adiponectina en cáncer pancreático: Revisión narrativa
DOI:
https://doi.org/10.29057/icsa.v14i28.16883Palabras clave:
Cáncer pancreático, tejido adiposo, adipocinas, inflamación, adiponectinaResumen
El tejido adiposo es considerado un importante órgano endocrino por su capacidad de secretar adipocinas al torrente sanguíneo. Una de ellas es la adiponectina, que ha mostrado posible asociación con la presencia de ciertas enfermedades. El cáncer de páncreas (CP), uno de los canceres más agresivos y con peor pronóstico, es una enfermedad que ha mostrado relación con niveles de adiponectina. Los estudios realizados a la fecha con adiponectina y CP, encuentran resultados contradictorios respecto a los niveles de adiponectina en la patología de CP. Algunos estudios asocian niveles elevados de adiponectina con CP, mientras que otros lo asocian a niveles reducidos de adiponectina, y otro más, muestran resultados inconcluyentes. Cabe mencionar que, en algunos estudios, depende el tipo de isoforma química de adiponectina la que se asocia con CP. A pesar de las inconsistencias entre investigaciones, se presenta como un marcador prometedor en combinación con otros parámetros, con potencial de aplicación diagnóstica, pronóstica y terapéutica. Por tal motivo, en este estudio se realizó una revisión de los diversos estudios publicados a la fecha, mostrando en conjunto la información con la finalidad de encontrar las áreas de oportunidad en cada uno de los estudios, para orientar a planificar nuevos estudios que permitan aportar información a dilucidar si la adiponectina es un biomarcador confiable y relevante, con un comportamiento protector, neutro o facilitador de la progresión tumoral, o si es consecuencia de un entorno metabólicamente alterado.
Descargas
Citas
Referencias
[1] FrigoletME, Gutiérrez-Aguilar R. Los colores del tejido adiposo. Gac Med Mex. 2020;156(2):142–149.
[2] Rodríguez-Díaz A, Diéguez C, López M, Freire-Agulleiro Ó. FAcTs on fire: Exploring thermogenesis. Adv Genet. 2025;113:172-98.
[3] KershawEE, Flier JS. Adipose Tissue as an Endocrine Organ. The Journal Of ClinicalEndocrinology & Metabolism [Internet]. 2004;89(6):2548-56.
[4] Guerre-Millo M. Adipose tissue hormones. J Endocrinol Invest. 2002;25(10):855-61.
[5] WangX, Zhang S, Li Z. Adipokines in glucose and lipid metabolism. Adipocyte. 2023;12: 1-1.
[6] Corrêa LH, Heyn GS, Magalhaes KG. The Impact of the Adipose Organ Plasticity on Inflammation and Cancer Progression. Cells. 2019;8(7):662.
[7] Lago F, Dieguez C, Gómez-Reino J, Gualillo O. Adipokines as emerging mediators of immune response and inflammation. Nat Clin Pract Rheumatol. 2007;3(12):716-24.
[8] Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006;6(10):772-83.
[9] Mercer JG, Moar KM, Rayner DV, Trayhurn P, Hoggard N. Regulation of leptin receptor and NPY gene expression in hypothalamus of leptin-treated obese (ob/ob) and cold-exposed lean mice. FEBS Lett. 1997;402(2-3):185-8.
[10] Paz-Filho G, Lim EL, Wong ML, Licinio J. Associations between adipokines and obesity-related cancer. Front Biosci Landmark Ed. 2011;16(5):1634-50.
[11] Kim JW, Kim JH, Lee YJ. The Role of Adipokines in Tumor Progression and Its Association with Obesity. Biomedicines. 2024;12(1):97.
[12] Kim DS, Scherer PE. Obesity, Diabetes, and Increased Cancer Progression. Diabetes Metab J. 2021;45(6):799-812.
[13] Kim DS, Scherer PE. Obesity, Diabetes, and Increased Cancer Progression. Diabetes Metab J. 2021;45(6):799-812.
[14] Toussirot É, Michel F, Binda D, Dumoulin G. The role of leptin in the pathophysiology of rheumatoid arthritis. Life Sci. 2015;140:29-36.
[15] Vansaun MN. Molecular pathways: adiponectin and leptin signaling in cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2013;19(8):1926-32.
[16] Stofkova A. Leptin and adiponectin: from energy and metabolic dysbalance to inflammation and autoimmunity. Endocr Regul. 2009;43(4):157-68.
[17] Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000;20(6):1595-9.
[18] Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation. 2003;107(5):671-4.
[19] Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol JASN. 2002;13(1):134-41.
[20] Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab. 2004;89(3):1102-7.
[21] Obesity and overweight [Internet]. [citado 21 de julio de 2025]. Disponible en: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
[22] Bray GA, Kim KK, Wilding JPH, World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev Off J Int Assoc Study Obes. 2017;18(7):715-23.
[23] Fang X, Wei J, He X, Lian J, Han D, An P, et al. Quantitative association between body mass index and the risk of cancer: A global Meta-analysis of prospective cohort studies. Int J Cancer. 2018;143(7):1595-603.
[24] Krupa-Kotara K, Dakowska D. Impact of obesity on risk of cancer. Cent Eur J Public Health. 2021;29(1):38-44.
[25] Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358(11):1148-59.
[26] Brown JS, Amend SR, Austin RH, Gatenby RA, Hammarlund EU, Pienta KJ. Updating the Definition of Cancer. Mol Cancer Res MCR. 2023;21(11):1142-7.
[27] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49.
[28] Bond-Smith G, Banga N, Hammond TM, Imber CJ. Pancreatic adenocarcinoma. BMJ. 2012;344:e2476.
[29] Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, et al. Pancreatic cancer. Nat Rev Dis Primer. 2016;2:16022.
[30] Lippi G, Mattiuzzi C. The global burden of pancreatic cancer. Arch Med Sci AMS. 2020;16(4):820-4.
[31] Haeberle L, Esposito I. Pathology of pancreatic cancer. Transl Gastroenterol Hepatol. 2019;4:50.
[32] Felsenstein M, Noë M, Masica DL, Hosoda W, Chianchiano P, Fischer CG, et al. IPMNs with co-occurring invasive cancers: neighbours but not always relatives. Gut. 2018;67(9):1652-62.
[33] Basturk O, Hong SM, Wood LD, Adsay NV, Albores-Saavedra J, Biankin AV, et al. A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas. Am J Surg Pathol. 2015;39(12):1730-41.
[34] Li X, Zhang Y, Yan Z, Jiang W, Rui S. Global, regional and national burden of pancreatic cancer and its attributable risk factors from 2019 to 2021, with projection to 2044. Front Oncol. 14 de enero de 2025;14. [35. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913-21.
[36] Sánchez Morales GE, Moguel Valladares RA, Flores Maza J, Clemente Gutiérrez U, Sánchez-García Ramos E, Domínguez Rosado I, et al. Pancreatic ductal adenocarcinoma: Eleven years of experience at a tertiary care hospital center. Rev Gastroenterol México. 2021;86(2):118-24.
[37] Huang J, Lok V, Ngai CH, Zhang L, Yuan J, Lao XQ, et al. Worldwide Burden of, Risk Factors for, and Trends in Pancreatic Cancer. Gastroenterology. 2021;160(3):744-54.
[38] Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18(7):493-502.
[39] Ushio J, Kanno A, Ikeda E, Ando K, Nagai H, Miwata T, et al. Pancreatic Ductal Adenocarcinoma: Epidemiology and Risk Factors. Diagnostics. 2021;11(3):562.
[40] González-Santiago O, Yeverino-Gutiérrez ML, Del Rosario González-González M, Corral-Symes R, Morales-San-Claudio PC. Mortality assessment of patients with pancreatic cancer in Mexico, 2000-2014. Ecancermedicalscience. 2017;11:788.
[41] Zhang CY, Liu S, Yang M. Clinical diagnosis and management of pancreatic cancer: Markers, molecular mechanisms, and treatment options. World J Gastroenterol. 2022;28(48):6827-45.
[42] Lemecha M, Chalise JP, Takamuku Y, Zhang G, Yamakawa T, Larson G, et al. Lcn2 mediates adipocyte-muscle-tumor communication and hypothermia in pancreatic cancer cachexia. Mol Metab. 2022;66:101612.
[43] Ureña JF. Cancer de pancreas. Rev Medica Sinerg. 2017;2(8):8.
[44] GBD 2017 Pancreatic Cancer Collaborators. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2019;4(12):934-47.
[45] Stoffel EM, Brand RE, Goggins M. Pancreatic Cancer: Changing Epidemiology and New Approaches to Risk Assessment, Early Detection, and Prevention. Gastroenterology. abril de 2023;164(5):752-65.
[46] Zhao Z, Liu W. Pancreatic Cancer: A Review of Risk Factors, Diagnosis, and Treatment. Technol Cancer Res Treat. 2020;19:1533033820962117.
[47] NCCN Guidelines for Patients: Pancreatic Cancer. Pancreat Cancer. 2025.
[48] Park W, Chawla A, O’Reilly EM. Pancreatic Cancer: A Review. JAMA. 2021;326(9):851-62.
[49] Walter FM, Mills K, Mendonça SC, Abel GA, Basu B, Carroll N, et al. Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM pancreatic study): a prospective cohort study. Lancet Gastroenterol Hepatol. 2016;1(4):298-306.
[50] Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817-25.
[51] Lee ES, Lee JM. Imaging diagnosis of pancreatic cancer: a state-of-the-art review. World J Gastroenterol. 2014;20(24):7864-77.
[52] Wang XY, Yang F, Jin C, Guan YH, Zhang HW, Fu DL. The value of 18F-FDG positron emission tomography/computed tomography on the pre-operative staging and the management of patients with pancreatic carcinoma. Hepatogastroenterology. 2014;61(135):2102-9.
[53] Banafea O, Mghanga FP, Zhao J, Zhao R, Zhu L. Endoscopic ultrasonography with fine-needle aspiration for histological diagnosis of solid pancreatic masses: a meta-analysis of diagnostic accuracy studies. BMC Gastroenterol. 2016;16(1):108.
[54] McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018;24(43):4846-61.
[55] Ohara Y, Valenzuela P, Hussain SP. The interactive role of inflammatory mediators and metabolic reprogramming in pancreatic cancer. Trends Cancer. 2022;8(7):556-69.
[56] Jiang J, Fan Y, Zhang W, Shen Y, Liu T, Yao M, et al. Adiponectin Suppresses Human Pancreatic Cancer Growth through Attenuating the β-Catenin Signaling Pathway. Int J Biol Sci. 2019;15(2):253-64.
[57] Quail DF, Dannenberg AJ. The obese adipose tissue microenvironment in cancer development and progression. Nat Rev Endocrinol. 2019;15(3):139-54.
[58] Nieman KM, Romero IL, Van Houten B, Lengyel E. Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta. 2013;1831(10):1533-41.
[59] Hemat Jouy S, Mohan S, Scichilone G, Mostafa A, Mahmoud AM. Adipokines in the Crosstalk between Adipose Tissues and Other Organs: Implications in Cardiometabolic Diseases. Biomedicines. 2024;12(9):2129.
[60] Wang ZV, Scherer PE. Adiponectin, the past two decades. J Mol Cell Biol. 2016;8(2):93-100.
[61] Straub LG, Scherer PE. Metabolic Messengers: Adiponectin. Nat Metab. 2019;1(3):334-9.
[62] Mizuno S, Nakai Y, Ishigaki K, Saito K, Oyama H, Hamada T, et al. Screening Strategy of Pancreatic Cancer in Patients with Diabetes Mellitus. Diagn Basel Switz. 2020;10(8):572.
[63] Bocian-Jastrzębska A, Malczewska-Herman A, Kos-Kudła B. Role of Leptin and Adiponectin in Carcinogenesis. Cancers. 2023;15(17):4250.
[64] Zhu N, Pankow JS, Ballantyne CM, Couper D, Hoogeveen RC, Pereira M, et al. High-molecular-weight adiponectin and the risk of type 2 diabetes in the ARIC study. J Clin Endocrinol Metab. 2010;95(11):5097-104.
[65] Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem. 2004;279(13):12152-62.
[66] Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr Rev. 2012;33(4):547-94.
[67] Huang B, Cheng X, Wang D, Peng M, Xue Z, Da Y, et al. Adiponectin promotes pancreatic cancer progression by inhibiting apoptosis via the activation of AMPK/Sirt1/PGC-1α signaling. Oncotarget. 2014;5(13):4732-45.
[68] Kim MJ, Jang SJ, Yu E. Loss of E-cadherin and cytoplasmic-nuclear expression of beta-catenin are the most useful immunoprofiles in the diagnosis of solid-pseudopapillary neoplasm of the pancreas. Hum Pathol. 2008;39(2):251-8.
[69] Helal NS, Maher S, Samir S, Elmeligy HA, Aboul-Ezz MA, Aboushousha T, et al. Assessing the diagnostic potential of SATB2 and β-catenin as biomarkers and therapeutic targets in pancreatic ductal adenocarcinoma. J Cancer Res Clin Oncol. 2025;151(2):56.
[70] Sciety [Internet]. 2025 [citado 25 de abril de 2026]. Expression of β-catenin, LEF-1, MMP7 and SFRP5 associated with poor outcome in pancreatic cancer. Disponible en: https://labs.sciety.org/articles/by?article_doi=10.21203/rs.3.rs-7509669/v1
[71] Wang CY, Tsai AC, Peng CY, Chang YL, Lee KH, Teng CM, et al. Dehydrocostuslactone suppresses angiogenesis in vitro and in vivo through inhibition of Akt/GSK-3β and mTOR signaling pathways. PloS One. 2012;7(2):e31195.
[72] Jope RS, Yuskaitis CJ, Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res. 2007;32(4-5):577-95.
[73] Huang B, Cheng X, Wang D, Peng M, Xue Z, Da Y, et al. Adiponectin promotes pancreatic cancer progression by inhibiting apoptosis via the activation of AMPK/Sirt1/PGC-1α signaling. Oncotarget. 2014;5(13):4732-45.
[74] Vazquez F, Lim JH, Chim H, Bhalla K, Girnun G, Pierce K, et al. PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell. 2013;23(3):287-301.
[75] Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Mootha V, et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell. 1999;98(1):115-24.
[76] Devaraj S, Swarbrick MM, Singh U, Adams-Huet B, Havel PJ, Jialal I. CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers. Am J Clin Pathol. 2008;129(5):815-22.
[77] Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999;100(25):2473-6.
[78] Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012;122(3):787-95.
[79] Odegaard JI, Chawla A. Mechanisms of macrophage activation in obesity-induced insulin resistance. Nat Clin Pract Endocrinol Metab. 2008;4(11):619-26.
[80] Lieu C, Heymach J, Overman M, Tran H, Kopetz S. Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17(19):6130-9.
[81] Hernández-Díaz Y, de Los Ángeles Ovando-Almeida M, Fresán A, Juárez-Rojop IE, Genis-Mendoza AD, Nicolini H, et al. Increased Leptin Levels in Plasma and Serum in Patients with Metabolic Disorders: A Systematic Review and Meta-Analysis. Int J Mol Sci. 2024;25(23):12668.
[82] Yang WH, Chen JC, Hsu KH, Lin CY, Wang SW, Wang SJ, et al. Leptin increases VEGF expression and enhances angiogenesis in human chondrosarcoma cells. Biochim Biophys Acta. 2014;1840(12):3483-93.
[83] Chang MC, Chang YT, Su TC, Yang WS, Chen CL, Tien YW, et al. Adiponectin as a potential differential marker to distinguish pancreatic cancer and chronic pancreatitis. Pancreas. 2007;35(1):16-21.
[84] Dalamaga M, Migdalis I, Fargnoli JL, Papadavid E, Bloom E, Mitsiades N, et al. Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case-control study. Cancer Causes Control CCC. 2009;20(5):625-33.
[85] Dranka-Bojarowska D, Lekstan A, Olakowski M, Jablonska B, Lewinski A, Musialski P, et al. The assessment of serum concentration of adiponectin, leptin and serum carbohydrate antigen-19.9 in patients with pancreatic cancer and chronic pancreatitis. J Physiol Pharmacol Off J Pol Physiol Soc. 2015;66(5):653-63.
[86] Gasiorowska A, Talar-Wojnarowska R, Kaczka A, Borkowska A, Czupryniak L, Małecka-Panas E. Subclinical Inflammation and Endothelial Dysfunction in Patients with Chronic Pancreatitis and Newly Diagnosed Pancreatic Cancer. Dig Dis Sci. 2016;61(4):1121-9.
[87] Oldfield L, Evans A, Rao RG, Jenkinson C, Purewal T, Psarelli EE, et al. Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic cancer detection in new-onset diabetes. EBioMedicine. 2022;75:103802.
[88] Mizuno S, Nakai Y, Isayama H, Yoshikawa T, Saito K, Takahara N, et al. Visceral adiposity and high adiponectin levels are associated with the prevalence of pancreatic cystic lesions. Int J Obes 2005. 2019;43(1):169-75.
[89] Stolzenberg-Solomon RZ, Weinstein S, Pollak M, Tao Y, Taylor PR, Virtamo J, et al. Prediagnostic adiponectin concentrations and pancreatic cancer risk in male smokers. Am J Epidemiol. 2008;168(9):1047-55.
[90] Dimou NL, Papadimitriou N, Mariosa D, Johansson M, Brennan P, Peters U, et al. Circulating adipokine concentrations and risk of five obesity-related cancers: A Mendelian randomization study. Int J Cancer. 2021;148(7):1625-36.
[91] Grote VA, Rohrmann S, Dossus L, Nieters A, Halkjaer J, Tjønneland A, et al. The association of circulating adiponectin levels with pancreatic cancer risk: a study within the prospective EPIC cohort. Int J Cancer. 2012;130(10):2428-37.
[92] Kadri Colakoglu M, Bostanci EB, Ozdemir Y, Dalgic T, Aksoy E, Ozer I, et al. Roles of adiponectin and leptin as diagnostic markers in pancreatic cancer. Bratisl Lek Listy. 2017;118(7):394-8.
[93] White DL, Hoogeveen RC, Chen L, Richardson P, Ravishankar M, Shah P, et al. A prospective study of soluble receptor for advanced glycation end products and adipokines in association with pancreatic cancer in postmenopausal women. Cancer Med. 2018;7(5):2180-91.
[94] Nogueira LM, Newton CC, Pollak M, Silverman DT, Albanes D, Männistö S, et al. Serum C-peptide, Total and High Molecular Weight Adiponectin, and Pancreatic Cancer: Do Associations Differ by Smoking? Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2017;26(6):914-22.
[95] The Role of Adipokines in Health and Disease - PMC [Internet]. [citado 31 de julio de 2025]. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC10216288/
[96] Pezzilli R, Barassi A, Corsi MM, Morselli-Labate AM, Campana D, Casadei R, et al. Serum leptin, but not adiponectin and receptor for advanced glycation end products, is able to distinguish autoimmune pancreatitis from both chronic pancreatitis and pancreatic neoplasms. Scand J Gastroenterol. 2010;45(1):93-9.
[97] Krechler T, Zeman M, Vecka M, Macasek J, Jachymova M, Zima T, et al. Leptin and adiponectin in pancreatic cancer: connection with diabetes mellitus. Neoplasma. 2011;58(1):58-64.
[98] van Andel M, Heijboer AC, Drent ML. Adiponectin and Its Isoforms in Pathophysiology. Adv Clin Chem. 2018;85:115-47.
[99] Achari AE, Jain SK. Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction. Int J Mol Sci. 2017;18(6):1321.
[100] Ellulu MS, Patimah I, Khaza’ai H, Rahmat A, Abed Y. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci AMS. 2017;13(4):851-63.
[101] Cheng H, Wang M, Su J, Li Y, Long J, Chu J, et al. Lipid Metabolism and Cancer. Life. 2022;12(6):784.
[102] Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26(3):439-51.
[103] Kalkman HO. An Explanation for the Adiponectin Paradox. Pharmaceuticals. 2021;14(12):1266.
[104] Suzuki S, Wilson-Kubalek EM, Wert D, Tsao TS, Lee DH. The Oligomeric Structure of High Molecular Weight Adiponectin. FEBS Lett. 2007;581(5):809-14.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2026 María Julia Rodriguez-Gomez, Abril Ramírez-Onofre , Luis Eduardo Villalobos-Guerrero, Ixtlixochitl Flores-Fong, Edgar Ricardo Valdivia-Tangarife, Fabiola Gonzalez-Ponce
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
